You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Aarti Drugs Q2 PAT soars 133% to Rs 75 cr

Capital Market 

On a consolidated basis, Aarti Drugs' net profit spurted 132.96% to Rs 75.27 crore on 21.07% increase in net sales to Rs 578.11 crore in Q2 September 2020 over Q2 September 2019.

Profit before tax (PBT) stood at Rs 97.12 crore, a 102% jump over Rs 47.87 crore reported in the same period last year. Total tax expense grew 40.5% year on year to Rs 21.85 crore in Q2 September 2020. The result was announced after market hours on Friday, 23 October 2020.

The board of the company has recommended an interim dividend of Rs 2.5 per equity share.

The board also passed an enabling resolution for raising upto Rs 350 crore by issuing equity shares or any other instruments or security including fully/partly convertible debentures or by way of a composite issue of non-convertible debentures through qualified institutions placement, private placement/public issue of equity/debt securities or through any other permissible mode.

Shares of Aarti Drugs fell 0.09% to Rs 748.75 on Friday.

Aarti Drugs is a pharmaceutical company. The company has a strong presence in the anti-diarrhea, anti-inflammatory therapeutic groups.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, October 24 2020. 11:00 IST